Velocity sites and investigators have supported research for nine products that have received U.S. FDA approval in 2024.
These include, but are not limited to:
- Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), the first FDA-approved #MASH drug.
- Moderna’s mRESVIA, an mRNA RSV vaccine for adults 60 and older.
- Eli Lilly and Company’s Kisunla (donanemab) for patients with early symptomatic Alzheimer’s.
- Ipsen’s Iquirvo, the first primary biliary cholangitis treatment approved by the FDA in over a decade, with significant contributions from our own Kris Kowdley, MD, the primary investigator for the Phase 3 trial.
- Pfizer’s Penbraya, a meningococcal vaccine for people aged 10 to 25.
To date, Velocity sites and investigators have contributed to research for over 60 product approvals, including more than 20 since 2023.
Once again, we’re grateful to our patients, employees, clients, and partners who make this progress possible.
Join us on this journey to improve lives: VelocityClinical.com/careers
